Title of article
Origin and prognostic value of circulating KRAS mutations in lung cancer patients
Author/Authors
Gautschi، نويسنده , , O. and Huegli، نويسنده , , B. and Ziegler، نويسنده , , A. and Gugger، نويسنده , , M. and Heighway، نويسنده , , J. and Ratschiller، نويسنده , , Mark D. and Mack، نويسنده , , P.C. and Gumerlock، نويسنده , , P.H. and Kung، نويسنده , , H.J. and Stahel، نويسنده , , R.A. and Gandara، نويسنده , , D.R. and Betticher، نويسنده , , D.C.، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2007
Pages
9
From page
265
To page
273
Abstract
Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP–PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.
Keywords
Circulating DNA , lung cancer , Mutation , KRAS
Journal title
Cancer Letters
Serial Year
2007
Journal title
Cancer Letters
Record number
1810680
Link To Document